Literature DB >> 11303921

The feasibility of maximum length sequences to reduce acquisition time of the middle latency response.

S L Bell1, R Allen, M E Lutman.   

Abstract

Maximum length sequences (MLS) have been used to improve the signal-to-noise ratio (SNR) of otoacoustic emissions [Thornton, J. Acoust. Soc. Am. 94, 132-136 (1993)] and the auditory brainstem response [Thornton and Slaven, Br. J. Audiol. 27, 205-210 (1993)]. By implication, a shorter recording time would be required to give equal signal-to-noise ratio (SNR). This study aimed to establish whether it is also possible to improve the SNR of the auditory-evoked potential termed the middle latency response (MLR) using maximum length sequences (MLS). Recordings of 180 s each were made using a conventional recording rate and MLS rates of 42, 89, and 185 clicks/s. Three different stimulus intensities were used in the range 30 to 70 dB nHL. The rate of 89 clicks/s was found to produce most improvement in SNR for both the Na-Pa region of the MLR and the Na-Pb region. This improvement in SNR using MLS implies that an MLS rate of 89 clicks/s would produce a fourfold reduction in recording time for equal SNR over conventional recording for the Pa-Nb region of the MLR at a stimulus intensity of 70 dB nHL. The latency of the Nb wave was found to reduce significantly using MLS. An MLR could not be recorded from every subject in this study, but more subjects had an identifiable response for MLS than for conventional recordings. Use of MLS to record the MLR appears to offer the potential for reduction in test time and better wave identification.

Entities:  

Mesh:

Year:  2001        PMID: 11303921     DOI: 10.1121/1.1340645

Source DB:  PubMed          Journal:  J Acoust Soc Am        ISSN: 0001-4966            Impact factor:   1.840


  1 in total

1.  Linear and nonlinear temporal interaction components of mid-latency auditory evoked potentials obtained with maximum length sequence stimulation.

Authors:  Brigitte A Lavoie; Angela Barks; A R D Thornton
Journal:  Exp Brain Res       Date:  2009-12-05       Impact factor: 1.972

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.